Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
Authors
Peidong Li
Jiaman Lin
Jianyun Nie (ORCID: https://orcid.org/0000-0003-4573-2793)
Yang Fan
Yongsheng Wang
Qinguo Mo
Xinshuai Wang
Yuee Teng
Huiping Li
J. Cheng
S. Zhou
J. Zhong
G. Yao
X. Zhu
Fei Ma
Ting Luo
Qiang Liu
Xiaojia Wang
Min Yan
Zhongsheng Tong
Qingyuan Zhang
Cuizhi Geng
Shusen Wang
Binghe Xu
Wei Li
Jin Yang
Quchang Ouyang
Tao Sun
Xinhong Wu
Xiaohua Zeng
Institutions
Hebei Medical University (CN)
Central South University (CN)
Harbin Medical University (CN)
Sun Yat-sen University (CN)
Chongqing University (CN)
Guangxi Medical University (CN)
Henan University of Science and Technology (CN)
Jilin University (CN)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Peking University (CN)
Sichuan University (CN)
Peking Union Medical College Hospital (CN)
Tianjin Medical University Cancer Institute and Hospital (CN)
Zhengzhou University (CN)
Peking University Cancer Hospital (CN)
Sun Yat-sen Memorial Hospital (CN)
Jilin Province Tumor Hospital (CN)
Zhejiang Cancer Hospital (CN)
Shandong Tumor Hospital (CN)
Nanfang Hospital (CN)
Third Affiliated Hospital of Harbin Medical University (CN)
Fourth Hospital of Hebei Medical University (CN)
Hunan Cancer Hospital (CN)
First Affiliated Hospital of Xi'an Jiaotong University (CN)
First Hospital of Jilin University (CN)
First Affiliated Hospital of GuangXi Medical University (CN)
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
Peidong Li, Jiaman Lin, Jianyun Nie, Yang Fan et al.
Citations
1 citations
Journal
BMJ
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
24.20
article
Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial
Peidong Li, Jiaman Lin, Jianyun Nie, Yang Fan, Yongsheng Wang, Qinguo Mo, Xinshuai Wang, Yuee Teng, Huiping Li, J. Cheng, S. Zhou, J. Zhong, G. Yao, X. Zhu, Fei Ma, Ting Luo, Qiang Liu, Xiaojia Wang, Min Yan, Zhongsheng Tong, Qingyuan Zhang, Cuizhi Geng, Shusen Wang, Binghe Xu, Wei Li, Jin Yang, Quchang Ouyang, Tao Sun, Xinhong Wu, Xiaohua Zeng
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
BMJVol. 392
Institutions
Hebei Medical University (CN), Central South University (CN), Harbin Medical University (CN), Sun Yat-sen University (CN), Chongqing University (CN), Guangxi Medical University (CN), Henan University of Science and Technology (CN), Jilin University (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Peking University (CN), Sichuan University (CN), Peking Union Medical College Hospital (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Zhengzhou University (CN), Peking University Cancer Hospital (CN), Sun Yat-sen Memorial Hospital (CN), Jilin Province Tumor Hospital (CN), Zhejiang Cancer Hospital (CN), Shandong Tumor Hospital (CN), Nanfang Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Fourth Hospital of Hebei Medical University (CN), Hunan Cancer Hospital (CN), First Affiliated Hospital of Xi'an Jiaotong University (CN), First Hospital of Jilin University (CN), First Affiliated Hospital of GuangXi Medical University (CN), Wuhan Union Hospital (CN), First Hospital of China Medical University (CN), Henan Cancer Hospital (CN), Sun Yat-sen University Cancer Center (CN), Jiangsu Hengrui Medicine (China) (CN), Chongqing Cancer Hospital (CN), Tumor Hospital of Guangxi Medical University (CN), Hubei Cancer Hospital (CN), Liaoning Cancer Hospital & Institute (CN), Shandong First Medical University (CN), Union Hospital (CN), Hefei First People's Hospital (CN), Southern Medical University (CN), China Medical University (CN)